As of 2025-09-16, the Intrinsic Value of Harmony Biosciences Holdings Inc (HRMY) is 51.94 USD. This HRMY valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 32.50 USD, the upside of Harmony Biosciences Holdings Inc is 59.80%.
The range of the Intrinsic Value is 38.29 - 90.34 USD
Based on its market price of 32.50 USD and our intrinsic valuation, Harmony Biosciences Holdings Inc (HRMY) is undervalued by 59.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 38.29 - 90.34 | 51.94 | 59.8% |
| DCF (Growth 10y) | 43.13 - 97.32 | 57.48 | 76.9% |
| DCF (EBITDA 5y) | 32.09 - 50.98 | 34.45 | 6.0% |
| DCF (EBITDA 10y) | 37.49 - 58.67 | 41.39 | 27.3% |
| Fair Value | 78.61 - 78.61 | 78.61 | 141.89% |
| P/E | 36.92 - 83.65 | 56.33 | 73.3% |
| EV/EBITDA | 30.17 - 50.48 | 34.24 | 5.4% |
| EPV | 29.69 - 39.43 | 34.56 | 6.3% |
| DDM - Stable | 27.04 - 90.63 | 58.84 | 81.0% |
| DDM - Multi | 26.11 - 69.30 | 38.08 | 17.2% |
| Market Cap (mil) | 1,869.73 |
| Beta | 1.25 |
| Outstanding shares (mil) | 57.53 |
| Enterprise Value (mil) | 1,495.77 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.13% |
| Cost of Debt | 7.00% |
| WACC | 8.81% |